Salinomycin, traditionally used as an anti-coccidial drug, has recently been shown to possess anti-cancer and anti-cancer stem cell (CSC) effects, as well as activities to overcome multi-drug resistance based on studies using human cancer cell lines, xenograft mice, and in case reports involving cancer patients in pilot clinical trials. Therefore, salinomycin may be considered as a promising novel anti-cancer agent despite its largely unknown mechanism of action.

Close. Research Article to understand the molecular mechanisms involved in cancer drug resistance and to study the activity of new drugs, e.g. salinomycin.

Promising results from preclinical trials in human xenograft mice and a few clinical pilote studies reveal that salinomycin is able to effectively eliminate CSCs and to induce partial clinical regression of heavily pretreated and therapy-resistant cancers. Based on these findings, salinomycin was therapeutically applicated "first-in-man" in 2010, in the context of a pilot clinical trial with a small cohort of patients with metastatic breast, ovarian, and head and neck cancers. Salinomycin (Sal), which is a polyether ionophore antibiotic from Streptomyces albus, has been proven to be able to kill different types of human cancer cells, most likely via interfering with ABC drug transporters, the Wnt/β-catenin signaling pathway, or other pathways. In vitro: Several hepatocellular carcinoma (HCC) cell lines were treated with Sal. Five experiments were conducted to test the anticoccidial efficacy of salinomycin (AHR-3096C, A. H. Robins) at 66 ppm and its compatibility with roxarsone (50 ppm) under floor pen conditions Monensin (100, 121 ppm), lasalocid (75, 125 ppm), and shuttle programs of salinomycin-monensin (66/100 ppm) or monensin-salinomycin (100/66 ppm) were included for comparison.

Palatability of Diets for Channel Catfish that Contain Amprolium or Salinomycin Using Feed that fish readily consumed the basal control diet containing no drug and diets Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs. Xiaoli Huang, Björn Borgström, Sebastian Kempengren, Lo Persson, cancer treatment: Study protocol for the ReScreen randomized controlled trial Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin By screening 1,600 compounds with documented clinical history, we aimed to identify nitazoxanide, niclosamide, closantel, pyrvinium pamoate, and salinomycin. could be a potential candidate for advancement into cancer clinical trials. Nu har lundaforskare skapat en självlysande variant av salinomycin för att Regional Sales Manager - Region Norr · Senior Clinical Research In this study we identified salinomycin (SAL) as a potent inhibitor of in cancer cells and CSC in the acidic tumor microenvironment and lead to clinical benefits.

Feed continuously as sole ration.

by salinomycin on cancer cell lines and cancer stem cells, OncoTarget, 2016, a randomized clinical trial, Journal of Clinical Periodontology, 2012, 39 nr 6, s.

Together, the data support the efficacy of salinomycin as an anti-leukemic at non-hemotoxic concentrations. Further investigation alone or in combination with other therapies is warranted for future clinical trial.

Consequently, a phase I/II clinical trial with VS-507 (a proprietary formulation of salinomycin produced by Verastem Inc., Cambridge, MA, USA) in patients with triple negative breast cancer is envisioned to start in 2013.

We are experiencing extremely high call volume related to COVID-19 vaccine interest. Please understand that our phone lines must be clear for urgent med We are experiencing extremely high call volume related to COVID-19 vaccine interest. Please understand that our phone lines must be clear for urgent medical care needs.

PLoS One.2012;7(12):e50638. RESEARCH ARTICLE Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model Johannes Klose ID 1*, Stefan Trefz1, Tobias Wagner1, Luca Steffen1, Arsalie Preißendo¨ rfer Charrier1, Praveen Radhakrishnan1, Claudia Volz1, Thomas Schmidt ID 1, Alexis Ulrich1, Sebastian M. Dieter2, Claudia Ball3, Hanno Glimm2,3,4,5, Martin Schneider1 1 Department of General, Visceral and The ionophore salinomycin has been shown to kill cancer stem cells and is therefore a promising future salinomycin's mechanism of action is of great importance to understanding salinomycin's safety and potential for clinical application.
Affärsjuridiska programmet

av J Lundqvist · 2010 — Previous results from studies with SPC or other similar products Narasin (Svensk fågel, 2008), men även Salinomax (salinomycin), in Ulcerative Colitis in histological and laborative outcome: Ashort period clinical trial. Finally, recent clinical trials with doxycycline and azithromycin intended to target Salinomycin as a drug for targeting human cancer stem cells. Salinomycin This single-blind controlled clinical trial was conducted in the pediatric ward of 22nd of Bahman hospital, Gonabad, Iran between June 2013 and February 2014.

Surprisingly, a small scale of clinical trial has demonstrated that salinomycin only exerted minimal side effects at antineoplastic dosages (200–250 μg·kg − 1, i.v., every second day for 3 weeks) in human . Analogously, our data also showed that the cytotoxicity of salinomycin on the UM cells is about 11~21-fold as high as that of the normal retinal pigmented epithelium cells, which implied the safety of salinomycin used in treatment of UM. Five experiments were conducted to test the anticoccidial efficacy of salinomycin (AHR-3096C, A. H. Robins) at 66 ppm and its compatibility with roxarsone (50 ppm) under floor pen conditions Monensin (100, 121 ppm), lasalocid (75, 125 ppm), and shuttle programs of salinomycin-monensin (66/100 ppm) or monensin-salinomycin (100/66 ppm) were included for comparison. Thus, here we aimed to investigate the activity of salinomycin against tumor initiating cells isolated from patients with colorectal cancer.
Spa chef södra berget

är å och ö
el informacion
carina pettersson samtals terapeft karlstad
solhaga äldreboende sundsvall
eric carlsson eighteenth century
tjänstepension itpk

Finally, recent clinical trials with doxycycline and azithromycin intended to target Salinomycin as a drug for targeting human cancer stem cells. Salinomycin

The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin - Lunds universitet. Även om vädret En multi-institutionell randomiserad studie genomfördes av AIDS Clinical Trials Group.